The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
NewAmsterdam Pharma (NAP), a clinical-stage biopharma company, is on a mission to transform patient care for populations suffering from metabolic diseases, particularly in areas where existing therapies have fallen short. With their lead investigational product, obicetrapib, NAP faced the complex task of conducting 11 studies, including three pivotal Phase III trials, across 51 countries. Managing the supply chain for these global trials while navigating regulatory hurdles—all without overburdening their internal teams—became a challenge.
With costs climbing and timelines tightening, the stakes were high. NAP needed a trusted partner who could not only streamline their operations but also ensure on-time, in-full delivery of investigational medicinal products (IMPs) for over 12,000 patients at 835 clinical sites. After exploring their options, they partnered with Thermo Fisher Scientific for support. Download our case study to explore how our comprehensive CDMO and CRO capabilities helped NAP tackle this multifaceted challenge, as well as the results of our collaboration.
